U.K. Court Refuses To Dismiss Patent Suit Over Growth Hormone
The court also denied a motion by Insmed and Avecia that attacked the validity of the patent protecting a Genentech growth hormone therapy that Tercica has licensed, the company said.
As is usual in such cases in the U.K., the court ordered Insmed and Avecia to pay legal fees incurred by Tercica and partner...
Already a subscriber? Click here to login